ScoreWhy is Concord Drugs Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 5.41%
- Poor long term growth as Operating profit has grown by an annual rate 9.20% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.76
2
With a growth in Net Profit of 825%, the company declared Outstanding results in Jun 26
- The company has declared positive results for the last 2 consecutive quarters
- PBT LESS OI(Q) At Rs 1.54 cr has Grown at 862.50%
- NET SALES(Q) At Rs 20.95 cr has Grown at 53.93%
- PAT(Q) Highest at Rs 1.11 cr.
3
With ROCE of 5.2, it has a Attractive valuation with a 1.8 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 18.94%, its profits have risen by 162% ; the PEG ratio of the company is 0.2
4
Promoter holding has decreased this quarter and now hold 45.08% of the company
5
Market Beating performance in long term as well as near term
- Along with generating 18.94% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Concord Drugs should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Concord Drugs for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Concord Drugs
18.85%
0.42
45.06%
Sensex
-9.23%
-0.68
13.60%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
21.06%
EBIT Growth (5y)
9.20%
EBIT to Interest (avg)
1.76
Debt to EBITDA (avg)
5.56
Net Debt to Equity (avg)
0.26
Sales to Capital Employed (avg)
0.90
Tax Ratio
28.32%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.64%
ROE (avg)
1.92%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
49
Industry P/E
38
Price to Book Value
2.06
EV to EBIT
25.17
EV to EBITDA
19.34
EV to Capital Employed
1.84
EV to Sales
1.31
PEG Ratio
0.19
Dividend Yield
NA
ROCE (Latest)
5.20%
ROE (Latest)
2.18%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend35What is working for the Company
PBT LESS OI(Q)
At Rs 1.54 cr has Grown at 862.50%
NET SALES(Q)
At Rs 20.95 cr has Grown at 53.93%
PAT(Q)
Highest at Rs 1.11 cr.
PBDIT(Q)
Highest at Rs 2.29 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 10.93%
EPS(Q)
Highest at Rs 0.84
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Concord Drugs
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 1.54 cr has Grown at 862.50%
Year on Year (YoY)MOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Net Sales - Quarterly
At Rs 20.95 cr has Grown at 53.93%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 1.54 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 1.11 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 2.29 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 10.93%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Earnings per Share (EPS) - Quarterly
Highest at Rs 0.84
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Footer loading
